专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017106189A1 COMPOSITIONS AND METHODS FOR TREATING RAS/MAPK MUTANT LUNG CANCER 审中-公开
标题翻译：治疗RAS / MAPK突变型肺癌的组合物和方法
公开(公告)号：WO2017106189A1
公开(公告)日：2017-06-22
申请号：PCT/US2016/066378
申请日：2016-12-13
申请人： HAHN, William C. , KRALL, Elsa Beyer , WANG, Belinda , AGUIRRE, Andrew , DANA-FARBER CANCER INSTITUTE, INC.
发明人： HAHN, William C. , KRALL, Elsa Beyer , WANG, Belinda , AGUIRRE, Andrew
IPC分类号： A61K31/5377 , A61K31/7088 , A61K45/06 , G01N33/50 , C12Q1/68
CPC分类号： A61K31/5377 , A61K31/416 , A61K31/437 , A61K31/506 , A61K31/517 , A61K31/519 , A61K45/00 , A61K45/06 , C12Q1/68 , C12Q1/6886 , C12Q2600/158 , G01N33/57423 , G01N2800/52 , A61K2300/00
摘要： The present invention features compositions and methods for typing an ALK-, BRAF-, EGFR-, NRAS-, or KRAS- or mutant lung cancer in a subject as a cancer sensitive or resistant to an ALK inhibitor, MEK inhibitor, BRAF inhibitor, or EGFR inhibitor, and related methods of treating such cancers. In particular embodiments, the present invention features compositions and methods for typing an ALK-, BRAF-, EGFR-, NRAS-, or KRAS-mutant lung cancer, determining whether a subject having an ALK-, BRAF-, EGFR-, NRAS-, or KRAS-mutant lung cancer is eligible for entry into a clinical trial for an ALK inhibitor, MEK inhibitor, BRAF inhibitor, or EGFR inhibitor, and monitoring effectiveness of treatment of an ALK-, BRAF-, EGFR-, NRAS-, or KRAS-mutant lung cancer. In some embodiments, the methods comprise measuring a level, copy number, or sequence of KEAP1 or NRF2 polynucleotide in a biological sample obtained from the subject relative to a reference level or sequence. The present invention also features compositions and methods for increasing sensitivity to an ALK inhibitor, MEK inhibitor, BRAF inhibitor, or EGFR inhibitor and treating an ALK-, BRAF-, EGFR-, NRAS-, or KRAS-mutant lung cancer.
摘要翻译：本发明的特征在于用于在受试者中将ALK-，BRAF-，EGFR-，NRAS-或KRAS-或突变型肺癌分类为对ALK抑制剂敏感或耐受的癌症的组合物和方法，MEK抑制剂，BRAF抑制剂或EGFR抑制剂，以及治疗这些癌症的相关方法。在具体的实施方案中，本发明描述了用于分型ALK-，BRAF-，EGFR-，NRAS-或KRAS-突变型肺癌的组合物和方法，确定具有ALK-，BRAF-，EGFR-，NRAS- ，或KRAS突变型肺癌适合进入ALK抑制剂，MEK抑制剂，BRAF抑制剂或EGFR抑制剂的临床试验，并监测ALK-，BRAF-，EGFR-，NRAS-或 KRAS突变型肺癌。在一些实施方案中，所述方法包括相对于参考水平或序列测量从受试者获得的生物样品中的KEAP1或NRF2多核苷酸的水平，拷贝数或序列。本发明还提供了用于增加对ALK抑制剂，MEK抑制剂，BRAF抑制剂或EGFR抑制剂的敏感性并治疗ALK-，BRAF-，EGFR-，NRAS-或KRAS-突变型肺癌的组合物和方法。

2. 发明申请

WO2012075069A2 SIGNATURES AND DETERMINANTS ASSOCIATED WITH CANCER AND METHODS OF USE THEREOF 审中-公开
标题翻译：与癌症相关的签名和决定因素以及使用方法
公开(公告)号：WO2012075069A2
公开(公告)日：2012-06-07
申请号：PCT/US2011062516
申请日：2011-11-30
申请人： DANA FARBER CANCER INST INC , HAHN WILLIAM C , TAMAYO PABLO , BOEHM JESSE S , MESIROV JILL P
发明人： HAHN WILLIAM C , TAMAYO PABLO , BOEHM JESSE S , MESIROV JILL P
IPC分类号： G01N33/574 , C12Q1/68 , G06F17/10 , G06F19/10
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158 , G06F19/18 , G06F19/20 , G06F19/24
摘要： The present invention provides methods of detecting cancer using biomarkers.
摘要翻译：本发明提供了使用生物标志物检测癌症的方法。

3. 发明申请

WO2008143894A3 PHOSPHORYLATED RALA 审中-公开
标题翻译：磷化镓
公开(公告)号：WO2008143894A3
公开(公告)日：2009-02-19
申请号：PCT/US2008006177
申请日：2008-05-14
申请人： DANA FARBER CANCER INST INC , HAHN WILLIAM C , CORRAL LAURA , SABLINA ANNA A
发明人： HAHN WILLIAM C , CORRAL LAURA , SABLINA ANNA A
IPC分类号： C07K16/18
CPC分类号： C07K16/32 , C12Q1/485 , G01N33/5748
摘要： Antibodies that are specific for human RalA that is phosphorylated at one or both of Ser183 and Ser194 are described as various methods such antibodies, including diagnostic methods and screening methods.
摘要翻译：在Ser183和Ser194中的一个或两个被磷酸化的人RalA特异的抗体被描述为各种方法，例如诊断方法和筛选方法。

4. 发明申请

WO2006084249A2 TELOMERASE RNA SUBUNIT AND METHODS OF USE THEREOF 审中-公开
标题翻译：端粒酶RNA亚单位及其使用方法
公开(公告)号：WO2006084249A2
公开(公告)日：2006-08-10
申请号：PCT/US2006/004188
申请日：2006-02-07
申请人： DANA-FARBER CANCER INSTITUTE , HAHN, William, C. , POSSEMATO, Richard , MASUTOMI, Kenkichi
发明人： HAHN, William, C. , POSSEMATO, Richard , MASUTOMI, Kenkichi
IPC分类号： C12N9/12 , C12N15/11
CPC分类号： C12N15/1137 , C12N9/1241 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y207/07049
摘要： The present invention provides a novel telomere associated RNA (hTERC-2) that mediates the DNA repair function of telomerase.
摘要翻译：本发明提供了介导端粒酶的DNA修复功能的新型端粒相关RNA（hTERC-2）。

5. 发明申请

WO2017074788A1 COMPOSITIONS AND METHODS FOR TARGETING CANCER-SPECIFIC SEQUENCE VARIATIONS 审中-公开
标题翻译：靶向癌症特异性序列变异的组合物和方法
公开(公告)号：WO2017074788A1
公开(公告)日：2017-05-04
申请号：PCT/US2016/057915
申请日：2016-10-20
申请人： THE BROAD INSTITUTE INC. , DANA-FARBER CANCER INSTITUTE, INC. , HAHN, William, C. , AGUIRRE, Andrew , COOK, April , COWLEY, Glenn , MEYERS, Robin , ROOT, David, E. , TSHERMIAK, Aviad , WEIR, Barbara , VAZQUEZ, Francisca
发明人： HAHN, William, C. , AGUIRRE, Andrew , COOK, April , COWLEY, Glenn , MEYERS, Robin , ROOT, David, E. , TSHERMIAK, Aviad , WEIR, Barbara , VAZQUEZ, Francisca
IPC分类号： C12Q1/68 , B82Y5/00
CPC分类号： C12Q1/6886 , A61K38/465 , A61K45/06 , A61K48/00 , B82Y5/00 , C12N9/22 , C12N9/96 , C12N15/1135 , C12N2320/34 , C12N2740/15043 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156
摘要： The present invention relates to compositions and methods for targeting cancer-specific DNA sequences, such as copy number amplifications and other types of cancer-specific sequence variations, such as cancer-specific polymorphisms, insertions, or deletions. The present invention provides hereto sequence-specific DNA targeting agents targeting a sequence within the amplified DNA region or a sequence otherwise specific for a cancer cell compared to a non- cancer cell. The invention further relates to methods for treating cancer, comprising administering such sequence-specific DNA targeting agents. The invention further relates to methods for preparing sequence-specific DNA targeting agent, as well as screening methods using the DNA targeting agents.
摘要翻译：本发明涉及用于靶向癌症特异性DNA序列的组合物和方法，例如拷贝数扩增和其他类型的癌症特异性序列变异，例如癌症特异性多态性，插入或缺失。本发明提供了靶向扩增的DNA区域内的序列或与非癌细胞相比对癌细胞特异的序列的序列特异性DNA靶向剂。本发明进一步涉及治疗癌症的方法，包括施用这种序列特异性DNA靶向剂。本发明还涉及制备序列特异性DNA靶向剂的方法，以及使用DNA靶向剂的筛选方法。

6. 发明申请

WO2012075069A3 SIGNATURES AND DETERMINANTS ASSOCIATED WITH CANCER AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2012075069A3
公开(公告)日：2012-06-07
申请号：PCT/US2011/062516
申请日：2011-11-30
申请人： DANA-FARBER CANCER INSTITUTE, INC. , HAHN, William C. , TAMAYO, Pablo , BOEHM, Jesse S. , MESIROV, Jill P.
发明人： HAHN, William C. , TAMAYO, Pablo , BOEHM, Jesse S. , MESIROV, Jill P.
IPC分类号： G01N33/574 , C12Q1/68 , G06F17/10 , G06F19/10
摘要： The present invention provides methods of detecting cancer using biomarkers.

7. 发明申请

WO2008143894A2 PHOSPHORYLATED RALA 审中-公开
标题翻译：磷化镓
公开(公告)号：WO2008143894A2
公开(公告)日：2008-11-27
申请号：PCT/US2008/006177
申请日：2008-05-14
申请人： DANA-FARBER CANCER INSTITUTE, INC. , HAHN, William, C. , CORRAL, Laura , SABLINA, Anna, A.
发明人： HAHN, William, C. , CORRAL, Laura , SABLINA, Anna, A.
IPC分类号： C07K16/18
CPC分类号： C07K16/32 , C12Q1/485 , G01N33/5748
摘要： Antibodies that are specific for human RalA that is phosphorylated at one or both of Ser183 and Ser194 are described as various methods such antibodies, including diagnostic methods and screening methods.
摘要翻译：在Ser183和Ser194中的一个或两个被磷酸化的人RalA特异的抗体被描述为各种方法，例如诊断方法和筛选方法。

8. 发明申请

WO2006084249A3 TELOMERASE RNA SUBUNIT AND METHODS OF USE THEREOF 审中-公开
标题翻译： TELOMERASE RNA亚基及其使用方法
公开(公告)号：WO2006084249A3
公开(公告)日：2006-12-14
申请号：PCT/US2006004188
申请日：2006-02-07
申请人： DANA FARBER CANCER INST INC , HAHN WILLIAM C , POSSEMATO RICHARD , MASUTOMI KENKICHI
发明人： HAHN WILLIAM C , POSSEMATO RICHARD , MASUTOMI KENKICHI
IPC分类号： C12N9/12 , C12N15/113
CPC分类号： C12N15/1137 , C12N9/1241 , C12N2310/111 , C12N2310/14 , C12N2310/53 , C12Y207/07049
摘要： The present invention provides a novel telomere associated RNA (hTERC-2) that mediates the DNA repair function of telomerase.
摘要翻译：本发明提供了介导端粒酶的DNA修复功能的新型端粒相关RNA（hTERC-2）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式